Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Central Florida Pulmonary Group PA

Neither a doctor nor a teaching hospital

Research payments

$2,021,773

202 payments

Through program year 2025, Central Florida Pulmonary Group PA is reported as receiving $2,021,773 in research payments, across 202 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $67,544 16
2024 Research $285,605 35
2023 Research $294,210 37
2022 Research $558,348 44
2021 Research $379,763 29
2020 Research $354,853 29
2019 Research $81,450 12

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $646,578 42 payments
  2. Vertex Pharmaceuticals Incorporated $597,169 20 payments
  3. Kadmon Corporation LLC $310,327 9 payments
  4. Genentech, Inc. $153,123 27 payments
  5. Amgen Inc. $58,199 3 payments
  6. Insmed, Inc. $36,688 22 payments
  7. GlaxoSmithKline, LLC. $36,569 10 payments
  8. Teva Pharmaceuticals USA, Inc. $34,511 17 payments
  9. Roche Products Limited $30,745 7 payments
  10. Inspire Medical Systems, Inc. $29,050 17 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis $318,382 10 payments
  2. A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis $231,243 3 payments
  3. A Randomized Phase 2 Open Label Multicenter Study to Evaluate the Safety Tolerability and Activity of KD025 in Subjects with Idiopathic Pulmonary Fibrosis (IPF) $224,578 4 payments
  4. A Phase 4 Study to Compare US Marketed Creon Drug Product with Drug Product Manufactured with a Modernized Process at an Alternate Manufacturing Site and with Drug Product Manufactured with the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Subjects with EPI due to Cystic Fibrosis $190,489 13 payments
  5. A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation $119,684 4 payments
  6. A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF) $115,815 4 payments
  7. PH III Study to Evaluate the Efficacy and Safety of Astegolimab in COPD $108,696 19 payments
  8. M16-111 $105,874 11 payments
  9. A Randomized Phase 2 Open Label Multicenter Study to Evaluate the Safety Tolerability and Activity of KD025 in Subjects with Idiopathic Pulmonary Fibrosis IPF $85,749 5 payments
  10. A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy $81,811 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record